Cargando…
Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination
BACKGROUND: Emerging ferroptosis-driven therapies based on nanotechnology function either by increasing intracellular iron level or suppressing glutathione peroxidase 4 (GPX4) activity. Nevertheless, the therapeutic strategy of simultaneous iron delivery and GPX4 inhibition remains challenging and h...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416514/ https://www.ncbi.nlm.nih.gov/pubmed/37563614 http://dx.doi.org/10.1186/s12951-023-01998-w |
_version_ | 1785087796921237504 |
---|---|
author | Rao, Zhiping Xia, Yutian Jia, Qian Zhu, Yutong Wang, Lexuan Liu, Guohuan Liu, Xuelan Yang, Peng Ning, Pengbo Zhang, Ruili Zhang, Xianghan Qiao, Chaoqiang Wang, Zhongliang |
author_facet | Rao, Zhiping Xia, Yutian Jia, Qian Zhu, Yutong Wang, Lexuan Liu, Guohuan Liu, Xuelan Yang, Peng Ning, Pengbo Zhang, Ruili Zhang, Xianghan Qiao, Chaoqiang Wang, Zhongliang |
author_sort | Rao, Zhiping |
collection | PubMed |
description | BACKGROUND: Emerging ferroptosis-driven therapies based on nanotechnology function either by increasing intracellular iron level or suppressing glutathione peroxidase 4 (GPX4) activity. Nevertheless, the therapeutic strategy of simultaneous iron delivery and GPX4 inhibition remains challenging and has significant scope for improvement. Moreover, current nanomedicine studies mainly use disulfide-thiol exchange to deplete glutathione (GSH) for GPX4 inactivation, which is unsatisfactory because of the compensatory effect of continuous GSH synthesis. METHODS: In this study, we design a two-in-one ferroptosis-inducing nanoplatform using iron-based metal-organic framework (MOF) that combines iron supply and GPX4 deactivation by loading the small molecule buthionine sulfoxide amine (BSO) to block de novo GSH biosynthesis, which can achieve sustainable GSH elimination and dual ferroptosis amplification. A coated lipid bilayer (L) can increase the stability of the nanoparticles and a modified tumor-homing peptide comprising arginine-glycine-aspartic acid (RGD/R) can achieve tumor-specific therapies. Moreover, as a decrease in GSH can alleviate resistance of cancer cells to chemotherapy drugs, oxaliplatin (OXA) was also loaded to obtain BSO&OXA@MOF-LR for enhanced cancer chemo-ferrotherapy in vivo. RESULTS: BSO&OXA@MOF-LR shows a robust tumor suppression effect and significantly improved the survival rate in 4T1 tumor xenograft mice, indicating a combined effect of dual amplified ferroptosis and GSH elimination sensitized apoptosis. CONCLUSION: BSO&OXA@MOF-LR is proven to be an efficient ferroptosis/apoptosis hybrid anti-cancer agent. This study is of great significance for the clinical development of novel drugs based on ferroptosis and apoptosis for enhanced cancer chemo-ferrotherapy. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-01998-w. |
format | Online Article Text |
id | pubmed-10416514 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-104165142023-08-12 Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination Rao, Zhiping Xia, Yutian Jia, Qian Zhu, Yutong Wang, Lexuan Liu, Guohuan Liu, Xuelan Yang, Peng Ning, Pengbo Zhang, Ruili Zhang, Xianghan Qiao, Chaoqiang Wang, Zhongliang J Nanobiotechnology Research BACKGROUND: Emerging ferroptosis-driven therapies based on nanotechnology function either by increasing intracellular iron level or suppressing glutathione peroxidase 4 (GPX4) activity. Nevertheless, the therapeutic strategy of simultaneous iron delivery and GPX4 inhibition remains challenging and has significant scope for improvement. Moreover, current nanomedicine studies mainly use disulfide-thiol exchange to deplete glutathione (GSH) for GPX4 inactivation, which is unsatisfactory because of the compensatory effect of continuous GSH synthesis. METHODS: In this study, we design a two-in-one ferroptosis-inducing nanoplatform using iron-based metal-organic framework (MOF) that combines iron supply and GPX4 deactivation by loading the small molecule buthionine sulfoxide amine (BSO) to block de novo GSH biosynthesis, which can achieve sustainable GSH elimination and dual ferroptosis amplification. A coated lipid bilayer (L) can increase the stability of the nanoparticles and a modified tumor-homing peptide comprising arginine-glycine-aspartic acid (RGD/R) can achieve tumor-specific therapies. Moreover, as a decrease in GSH can alleviate resistance of cancer cells to chemotherapy drugs, oxaliplatin (OXA) was also loaded to obtain BSO&OXA@MOF-LR for enhanced cancer chemo-ferrotherapy in vivo. RESULTS: BSO&OXA@MOF-LR shows a robust tumor suppression effect and significantly improved the survival rate in 4T1 tumor xenograft mice, indicating a combined effect of dual amplified ferroptosis and GSH elimination sensitized apoptosis. CONCLUSION: BSO&OXA@MOF-LR is proven to be an efficient ferroptosis/apoptosis hybrid anti-cancer agent. This study is of great significance for the clinical development of novel drugs based on ferroptosis and apoptosis for enhanced cancer chemo-ferrotherapy. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-023-01998-w. BioMed Central 2023-08-10 /pmc/articles/PMC10416514/ /pubmed/37563614 http://dx.doi.org/10.1186/s12951-023-01998-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Rao, Zhiping Xia, Yutian Jia, Qian Zhu, Yutong Wang, Lexuan Liu, Guohuan Liu, Xuelan Yang, Peng Ning, Pengbo Zhang, Ruili Zhang, Xianghan Qiao, Chaoqiang Wang, Zhongliang Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination |
title | Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination |
title_full | Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination |
title_fullStr | Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination |
title_full_unstemmed | Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination |
title_short | Iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination |
title_sort | iron-based metal-organic framework co-loaded with buthionine sulfoximine and oxaliplatin for enhanced cancer chemo-ferrotherapy via sustainable glutathione elimination |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416514/ https://www.ncbi.nlm.nih.gov/pubmed/37563614 http://dx.doi.org/10.1186/s12951-023-01998-w |
work_keys_str_mv | AT raozhiping ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination AT xiayutian ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination AT jiaqian ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination AT zhuyutong ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination AT wanglexuan ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination AT liuguohuan ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination AT liuxuelan ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination AT yangpeng ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination AT ningpengbo ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination AT zhangruili ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination AT zhangxianghan ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination AT qiaochaoqiang ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination AT wangzhongliang ironbasedmetalorganicframeworkcoloadedwithbuthioninesulfoximineandoxaliplatinforenhancedcancerchemoferrotherapyviasustainableglutathioneelimination |